All In Biotech

Drug Trial Radar · NCT03914612

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 813 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

813

Actual

Start

Aug 22, 2019

Primary completion

Dec 16, 2022

Study completion Sep 26, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

Conditions

  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Dedifferentiated Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Recurrent Endometrial Adenocarcinoma
  • Recurrent Endometrial Carcinoma
  • Recurrent Endometrial Clear Cell Adenocarcinoma
  • Recurrent Endometrial Dedifferentiated Carcinoma
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Endometrial Mixed Cell Adenocarcinoma
  • Recurrent Endometrial Serous Adenocarcinoma
  • Recurrent Endometrial Undifferentiated Carcinoma
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions

  • CarboplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT scan

  • PaclitaxelDrug

    Given IV

  • PembrolizumabBiological

    Given IV

  • Placebo AdministrationOther

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.

Locations

397 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Community Cancer Institute

    Clovis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • City of Hope Antelope Valley

    Lancaster, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Eisenhower Medical Center

    Rancho Mirage, California

  • Mercy Regional Cancer Center

    Redding, California

  • Mercy Oncology Center

    Redding, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Kaiser Permanente Downtown Commons

    Sacramento, California

  • Mercy Cancer Center - Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente-San Diego Zion

    San Diego, California

  • Naval Medical Center -San Diego

    San Diego, California

  • Zuckerberg San Francisco General Hospital

    San Francisco, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Kaiser Permanente-San Francisco

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California

  • Kaiser Permanente San Leandro

    San Leandro, California

  • Kaiser Permanente-San Marcos

    San Marcos, California

Showing 40 of 397 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.